Expression of surfactant protein-A in exhaled breath condensate of patients with chronic obstructive pulmonary disease

Lin,Xue‑Feng; Zhang,Lei; Shi,Shu‑Yuan; Fan,Yi‑Chu; Wu,Zhen‑Lin; Zhang,Xun; Sun,Da‑Qiang

doi:10.3892/mmr.2015.4702

Expression of surfactant protein-A in exhaled breath condensate of patients with chronic obstructive pulmonary disease

Authors:
- Xue‑Feng Lin
- Lei Zhang
- Shu‑Yuan Shi
- Yi‑Chu Fan
- Zhen‑Lin Wu
- Xun Zhang
- Da‑Qiang Sun
View Affiliations

Affiliations: Department of Nursing, Tianjin Medical College, Tianjin 300222, P.R. China, Graduate School of Tianjin Medical University, Tianjin 300070, P.R. China, Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300222, P.R. China
Published online on: December 22, 2015 https://doi.org/10.3892/mmr.2015.4702
Pages: 1667-1672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pulmonary surfactant protein A (SP-A) has been associated with host defense in the lung, and contributes to the pathogenesis of chronic obstructive pulmonary disease (COPD). The present study aimed to determine a non‑invasive method of measurement of SP‑A, and further examine the expression levels of SP‑A in patients with COPD. SP‑A was detected in the exhaled breath condensate (EBC) obtained from patients with COPD and from non‑COPD subjects. The individuals recruited for the present study comprised 60 subjects with and without COPD, who underwent lobectomy for a solitary peripheral lung nodule. EBC was collected using a condenser, and an enzyme‑linked immunosorbent assay (ELISA) was used to measure the levels of SP‑A. Tissue samples were obtained during lobectomy through resection of the adjacent lung tissues, located >5 cm from the nodule. Western blot analysis and immunohistochemistry were used to measure SP‑A and SP‑A‑positive type II pneumocytes. The results demonstrated that SP‑A was detectable in the EBC of all subjects. The results of the ELISA and western blotting demonstrated that the expression levels of SP‑A were significantly decreased in patients with COPD, compared with the non‑COPD subjects. The reduction of SP‑A‑positive type II pneumocytes was associated with the expression levels of SP‑A. Decreased expression levels of SP‑A in EBC were associated with a higher degree of airway limitation. These results suggested that the measurement of SP‑A levels in the EBC may serve as a method for monitoring airway obstruction in patients with COPD. Further investigations are required in order to examine these observations further and to elucidate the underlying mechanisms.

View Figures

View References

1	Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Mar tinez FJ, Nishimura M, et al: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 187:347–365. 2013. View Article : Google Scholar
2	Barnes PJ: Chronic obstructive pulmonary disease. N Engl J Med. 343:269–280. 2000. View Article : Google Scholar : PubMed/NCBI
3	Pellegrino R and Brusasco V: On the causes of lung hyperinflation during bronchoconstriction. Eur Respir J. 10:468–475. 1997. View Article : Google Scholar : PubMed/NCBI
4	Baldi S, Miniati M, Bellina CR, Battolla L, Catapano G, Begliomini E, Giustini D and Giuntini C: Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 164:585–589. 2001. View Article : Google Scholar : PubMed/NCBI
5	Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koëter GH and Postma DS: Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J. 15:109–115. 2000. View Article : Google Scholar : PubMed/NCBI
6	Bhowmik A, Seemungal TA, Sapsford RJ, Devalia JL and Wedzicha JA: Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax. 53:953–956. 1998. View Article : Google Scholar
7	Saetta M, Turato G, Maestrelli P, Mapp CE and Fabbri LM: Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 163:1304–1309. 2001. View Article : Google Scholar : PubMed/NCBI
8	Wielders PL and Dekhuijzen PN: Disease monitoring in chronic obstructive pulmonary disease: Is there a role for biomarkers? Eur Respir J. 10:2443–2445. 1997. View Article : Google Scholar
9	Hunt J: Exhaled breath condensate: An evolving tool for noninvasive evaluation of lung disease. J Allergy Clin Immunol. 110:28–34. 2002. View Article : Google Scholar : PubMed/NCBI
10	Carter SR, Davis CS and Kovacs EJ: Exhaled breath condensate collection in the mechanically ventilated patient. Respir Med. 106:601–613. 2012. View Article : Google Scholar : PubMed/NCBI
11	Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA and Rubin BK: Effects of aerosolized surfactant in patients with stable chronic bronchitis: A prospective randomized controlled trial. JAMA. 278:1426–1431. 1997. View Article : Google Scholar : PubMed/NCBI
12	Bernhard W, Haslam PL and Floros J: From birds to humans: New concepts on airways relative to alveolar surfactant. Am J Respir Cell Mol Biol. 30:6–11. 2004. View Article : Google Scholar
13	Milic-Emili J: Does mechanical injury of the peripheral airways play a role in the genesis of COPD in smokers? COPD. 1:85–92. 2004. View Article : Google Scholar
14	Sin DD, Pahlavan PS and Man SF: Surfactant protein D: A lung specific biomarker in COPD? Ther Adv Respir Dis. 2:65–74. 2008. View Article : Google Scholar
15	Guo X, Lin HM, Lin Z, Montaño M, Sansores R, Wang G, DiAngelo S, Pardo A, Selman M and Floros J: Polymorphisms of surfactant protein gene A, B, D, and of SP-B-linked micro-satellite markers in COPD of a Mexican population. Chest. 117:249S–250S. 2000. View Article : Google Scholar
16	Otto-Verberne CJ, Ten Have-Opbroek AA, Franken C, Hermans J and Dijkman JH: Protective effect of pulmonary surfactant on elastase-induced emphysema in mice. Eur Respir J. 5:1223–1230. 1992.PubMed/NCBI
17	Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid KB, Madan T and Chakraborty T: Surfactant proteins SP-A and SP-D: Structure, function and receptors. Mol Immunol. 43:1293–1315. 2006. View Article : Google Scholar
18	Pastva AM, Wright JR and Williams KL: Immunomodulatory roles of surfactant proteins A and D: Implications in lung disease. Proc Am Thorac Soc. 4:252–257. 2007. View Article : Google Scholar : PubMed/NCBI
19	Honda Y, Takahashi H, Kuroki Y, Akino T and Abe S: Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest. 109:1006–1009. 1996. View Article : Google Scholar : PubMed/NCBI
20	Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y and Nishimura M: Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J. 24:964–970. 2004. View Article : Google Scholar : PubMed/NCBI
21	Vlachaki EM, Koutsopoulos AV, Tzanakis N, Neofytou E, Siganaki M, Drositis I, Moniakis A, Schiza S, Siafakas NM and Tzortzaki EG: Altered surfactant protein-A expression in type II pneumocytes in COPD. Chest. 137:37–45. 2010. View Article : Google Scholar
22	Rahman I and Biswas SK: Non-invasive biomarkers of oxidative stress: Reproducibility and methodological issues. Redox Rep. 9:125–143. 2004. View Article : Google Scholar : PubMed/NCBI
23	Celli BR and MacNee W; ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 23:932–946. 2004. View Article : Google Scholar : PubMed/NCBI
24	Mutti A, Corradi M, Goldoni M, Vettori MV, Bernard A and Apostoli P: Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest. 129:1288–1297. 2006. View Article : Google Scholar : PubMed/NCBI
25	Kharitonov SA and Barnes PJ: Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 163:1693–1722. 2001. View Article : Google Scholar : PubMed/NCBI
26	Jöbsis Q, Raatgeep HC, Schellekens SL, Kroesbergen A, Hop WC and de Jongste JC: Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment. Eur Respir J. 16:95–100. 2000. View Article : Google Scholar : PubMed/NCBI
27	Guo X, Lin HM, Lin Z, Montaño M, Sansores R, Wang G, DiAngelo S, Pardo A, Selman M and Floros J: Surfactant protein gene A, B and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J. 18:482–490. 2001. View Article : Google Scholar : PubMed/NCBI
28	Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllärniemi M and Kinnula VL: Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res. 7:5125–5132. 2008. View Article : Google Scholar
29	Wirtz HR and Schmidt M: Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. Eur Respir J. 9:24–32. 1996. View Article : Google Scholar : PubMed/NCBI
30	Subramaniam S, Whitsett JA, Hull W and Gairola CG: Alteration of pulmonary surfactant proteins in rats chronically exposed to cigarette smoke. Toxicol Appl Pharmacol. 140:274–280. 1996. View Article : Google Scholar : PubMed/NCBI
31	Garcia O, Hiatt MJ, Lundin A, Lee J, Reddy R, Navarro S, Kikuchi A and Driscoll B: Targeted type 2 alveolar cell depletion provides a dynamic functional model for lung injury repair. Am J Respir Cell Mol Biol. Jul 23–2015.Epub ahead of print. View Article : Google Scholar